4Koul A, Arnoult E, Lounis N, et aL The challenge of new drug discovery for tubercalosis[J].Nature, 2011,469(7331):483-490.
5Yount NY, Yeaman MR. Emerging themes and therapeutic prospects for anti-infective peptides[J].Annu RevPharmaeol, 2012,52:337-360.
6Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, T reearichi EM, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum- beta-laetamase production and inadequate initial antibiotic therapy[J].Antimicrob Agents Chemother, 2010,54:4085-91.
7Stefanie Van Aken, Nathalie Lund, Jonas Ahl. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia[J].Scandinavian Journal of infections Diseases, 2014,46:753-762.